Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Воробьева О.В. Дополнительное кратковременное введение бензодиазепиновых анксиолитиков в инициальном периоде лечения панического расстройства. Журн. неврологии и психиатрии им. С.С.Корсакова. 2006; 11: 39–41. / Vorob'eva O. V. Dopolnitel'noe kratkovremennoe vvedenie benzodiazepinovykh anksiolitikov v initsial'nom periode lecheniia panicheskogo rasstroistva. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 11: 39–41. [in Russian] 2. Воробьева О.В. Пути повышения эффективности терапии тревожных расстройств в клинике нервных болезней. Психиатрия и психофармакотерапия. 2016; 18 (1): 34–9. / Vorobyeva O.V. Efficacy enhancement in treatment of anxiety disorders in neurology. Psychiatry and Psychopharmacotherapy. 2016; 18 (1): 34–9. 3. Воронина Т.А., Калинина Т.С., Петрянина Е.В. Дифференцировочные стимульные свойства феназепама и лоразепама: специфичность и роль ГАМК-рецепторов. Эксперим. и клин. фармакология. 2008; 1: 3–7. / Voronina T.A., Kalinina T.S., Petrianina E.V. Differentsirovochnye stimul'nye svoistva fenazepama i lorazepama: spetsifichnost' i rol' GAMK-retseptorov. Eksperim. i klin. farmakologiia. 2008; 1: 3–7. [in Russian] 4. Ибатов А.Д. Влияние лоразепама на эмоциональный статус и качество жизни больных ишемической болезнью сердца. Кардиология. 2006; с. 11–4. / Ibatov A.D. Vliianie lorazepama na emotsional'nyi status i kachestvo zhizni bol'nykh ishemicheskoi bolezn'iu serdtsa. Kardiologiia. 2006; s. 11–4. [in Russian] 5. Иванов С.В., Бурлаков А.В., Ильина Н.А. Спектр терапевтической эффективности и безопасность применения лорафена при тревожных расстройствах. Журн. неврологии и психиатрии им. С.С.Корсакова. 2003; 8: 38–41. / Ivanov S.V., Burlakov A.V., Il'ina N.A. Spektr terapevticheskoi effektivnosti i bezopasnost' primeneniia lorafena pri trevozhnykh rasstroistvakh. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2003; 8: 38–41. [in Russian] 6. Клыгуль Т.А. и др. Экспериментальная характеристика спектра фармакологической активности транквилизатора лоразепама. Журн. невропатологии и психиатрии. 1975; 3: 435–8. / Klygul' T.A. i dr. Eksperimental'naia kharakteristika spektra farmakologicheskoi aktivnosti trankvilizatora lorazepama. Zhurn. nevropatologii i psikhiatrii. 1975; 3: 435–8. [in Russian] 7. Мацнев Э.И., Сигалева Е.Э. Современные тенденции в лечении ушного шума. Вестн. оториноларингологии. 2009; 4: 57–9. / Matsnev E.I., Sigaleva E.E. Sovremennye tendentsii v lechenii ushnogo shuma. Vestn. otorinolaringologii. 2009; 4: 57–9. [in Russian] 8. Нуллер Ю.Л., Михайленко И.Н. Аффективные психозы. Л.: Медицина, 1988. / Nuller Iu.L., Mikhailenko I.N. Affektivnye psikhozy. L.: Meditsina, 1988. [in Russian] 9. Сиволап Ю.П. Злоупотребление алкоголем и фармакотерапия алкоголизма. Неврология, нейропсихиатрия, психосоматика. 2014; 3: 4–9. / Sivolap Iu.P. Zloupotreblenie alkogolem i farmakoterapiia alkogolizma. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 3: 4–9. [in Russian] 10. Точилов В.А. Анксиолитики – недостающее звено в терапии психозов. Психиатрия и психофармакотерапия. 2006; 8 (4): 54–9. / Tochilov V.A. Anksiolitiki – nedostaiushchee zveno v terapii psikhozov. Psychiatry and Psychopharmacotherapy. 2006; 8 (40: 54–9. [in Russian] 11. Abry M, Piante M, Grossetete JL et al. Lorazepam, a new benzodiazepinic derivative. Study in a gastroenterology service. Lyon Med 1971; 226 (17): 581–3. 12. Andrade C, Reddy KP, Srihari BS et al. Effects of zopiclone and Lorazepam on ect seizure duration: clinical implications of findings from an animal model. Indian J Psychiatry 2000; 42 (3): 308–11. 13. Arora B, Kannikeswaran N. The serotonin syndrome – the need for physician's awareness. Int J Emerg Med 2010; 3 (4): 373–7. 14. Backonja M, Beinlich B, Dulli D et al. Haloperidol and lorazepam for the treatment of nausea and vomiting associated with the treatment of intractable migraine headaches. Arch Neurol 1989; 46 (7): 724. 15. Ballard C, Orrell M, YongZhong S et al. Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) Program. Am J Psychiatry 2016; 173 (3): 252–62. 16. Bhattacharyya N, Baugh RF, Orvidas L et al. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg 2008; 139 (5 Suppl. 4): S47–81. 17. Bleicher J, Bhaskara A, Huyck T et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. J Support Oncol 2008; 6 (1): 27–32. 18. Braestrup C, Squires RF. Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol 1978; 48 (3): 263–70. 19. Burkhalter E. Lorazepam as premedication for gastroscopy. Gastrointest Endosc 1989; 35 (1): 64–5. 20. Chang DH, Hiss S, Herich L et al. Implantation of venous access devices under local anesthesia: patients' satisfaction with oral lorazepam. Patient Prefer Adherence 2015; 9: 943–9. 21. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004; 65 (Suppl. 5): 7–12. 22. Cooper R, Gent P. An overview of chemotherapy-induced emesis highlighting the role of lorazepam as adjuvant therapy. Int J Palliat Nurs 2002; 8 (7): 331–5. 23. Cox B, Chhabra A, Adler M et al. Cannabinoid hyperemesis syndrome: case report of a paradoxical reaction with heavy marijuana use. Case Rep Med 2012; 2012: 757696. 24. Curtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord 2004; 78 (3): 201–8. 25. Defrancesco M, Marksteiner J, Fleischhacker WW et al. Use of Benzodiazepines in Alzheimer's Disease: A Systematic Review of Literature. Int J Neuropsychopharmacol 2015; 18 (10): pyv055. 26. Dhossche DM, Wachtel LE, Goetz M et al. Catatonia in psychiatric illnessess. In: H.Fatemi, P.Clayton, editors. The Medical Basis of Psychiatry. New York: Springer, 2014. 27. Frank C. Recognition and treatment of serotonin syndrome. Can Fam Physician 2008; 54 (7): 988–92. 28. Frighetto L, Marra C, Bandali S et al. An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients. Health Qual Life Outcomes 2004; 2: 17. 29. Gallos G, Yim P, Chang S et al. Targeting the restricted a-subunit repertoire of airway smooth muscle GABAA receptors augments airway smooth muscle relaxation. Am J Physiol Lung Cell Mol Physiol 2012; 302 (2): L248256. 30. Gershkovich P, Wasan KM, Ribeyre C et al. Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs Context 2015; 4: 212287. 31. Gillies D, Sampson S, Beck A et al. Benzodiazepines for psychosis-induced aggression or agitation.Cochrane Database Syst Rev 2013; 4: CD003079. 32. Goyal N, Thakur A, Sinha VK. Acute dystonia with intramuscular olanzapine in adolescent mania: a report. Aust N Z J Psychiatry 2005; 39 (11–12): 1046–7. 33. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 2013; 13 (2): 214–23. 34. Gupta MA, Gupta AK, Haberman HF. Psychotropic drugs in dermatology. A review and guidelines for use. J Am Acad Dermatol 1986; 14 (4): 633–45. 35. Hagen EM, Farbu E, Bindoff L. Acute dystonia caused by metoclopramide (Afipran) therapy. (Article in Norwegian). Tidsskr Nor Laegeforen 2001; 121 (18): 2162–3. 36. Hassan A, Ahlskog JE, Matsumoto JY et al. Orthostatic tremor: Clinical, electrophysiologic, and treatment findings in 184 patients. Neurology 2016; 86 (5): 458–64. 37. Hawkins JM, Archer KJ, Strakowski SM et al. Somatic treatment of catatonia. Int J Psychiatry Med 1995; 25 (4): 345–69. 38. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21 (8): 864–72. 39. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Int J Clin Pract 2009; 63 (7): 1085–94. 40. Irie M, Nagata S, Endo Y. Diazepam attenuates conditioned histamine release in guinea pigs. Int J Psychophysiol 2004; 51 (3): 231–8. 41. Jacobowski NL, Heckers S, Bobo WV. Delirious mania: detection, diagnosis, and clinical management in the acute setting. J Psychiatr Pract 2013; 19 (1): 15–28. 42. Jennum P, Baandrup L, Ibsen R et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. Eur Neuropsychopharmacol 2015; 25 (11): 1906–13. 43. Kaufmann WA, Humpel C, Alheid GF, Marksteiner J. Compartmentation of alpha 1 and alpha 2 GABA(A) receptor subunits within rat extended amygdala: implications for benzodiazepine action. Brain Res 2003; 964 (1): 91–9. 44. Kelly MD, Smith A, Banks G et al. Role of the histidine residue at position 105 in the human alpha 5 containing GABA(A) receptor on the affinity and efficacy of benzodiazepine site ligands. Br J Pharmacol 2002; 135 (1): 248–56. 45. Khouzam HR. Identification and management of tardive dyskinesia: A case series and literature review. Postgrad Med 2015; 127 (7): 726–37. 46. Kim SW, Shin IS, Kim JM et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006; 47 (5): 440–2. 47. Kishimoto S, Nakamura K, Arai T et al. Postoperative neuroleptic malignant syndrome-like symptoms improved with intravenous diazepam: a case report. J Anesth 2013; 27 (5): 768–70. 48. Krause L, Shuster S. Mechanism of action of antipruritic drugs. Br Med J (Clin Res Ed) 1983; 22: 1199–200. 49. Kumar CN, Andrade C, Murthy P. A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal. J Stud Alcohol Drugs 2009; 70 (3): 467–74. 50. Kyriakopoulos AA, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of lorazepam: a review. J Clin Psychiatry 1978; 39 (10 Pt. 2): 16–23. 51. Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S et al. Treat-ment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. Psychopharmacology (Berl) 1995; 120 (1): 109–15. 52. Laakmann G, Schüle C, Lorkowski G et al. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl) 1998; 136 (4): 357–66. 53. Laraki M, El Mouknia M, Bouaguad A et al. Prevention of postoperative nausea and vomiting by lorazepam. (Article in French). Cah Anesthesiol 1996; 44 (2): 159–62. 54. Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. Psy-chiatry Clin Neurosci 2015; 69 (6): 321–34. 55. Li Pi Shan RS, Ashworth NL. Comparison of lorazepam and zopiclone for insomnia in patients with stroke and brain injury: a randomized, crossover, double-blinded trial. Am J Phys Med Rehabil 2004; 83 (6): 421–7. 56. Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A et al. The clinical challenges of akathisia. CNS Spectr 2015; 20 (Suppl. 1): 1–14; quiz 15–16. 57. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008; 14 (2): 85–93. 58. Luchini F, Lattanzi L, Bartolommei N. Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Four case reports. J Nerv Ment Dis 2013; 201 (1): 36–42. 59. Martin JL, Sainz-Pardo M, Furukawa TA et al. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psycho-pharmacol 2007; 21 (7): 774–82. 60. Meyers C, Vranckx C, Elgen K. Psychosomatic disorders in general practice: comparisons of treatment with flupenthixol, diazepam and sulpiride. Pharmatherapeutica 1985; 4 (4): 244–50. 61. Miller M. Effect of an anxiolytic agent in hay fever. Acta Otorhinolaryngol Belg. 1975; 29 (3): 466–72. 62. Minen MT, Camprodon J, Nehme R et al. The neuropsychiatry of tinnitus: a circuit-based approach to the causes and treatments available. J Neurol Neurosurg Psychiatry 2014; 85 (10): 1138–44. 63. Park SH, Bang SM, Nam E et al. A randomized double-blind placebo-controlled study of low-dose intravenous Lorazepam to reduce procedural pain during bone marrow aspiration and biopsy. Pain Med 2008; 9 (2): 249–52. 64. Pelaia G, Di Paola ED, De Sarro G et al. Is the mitochondrial benzodiazepine receptor involved in the control of airway smooth muscle tone? Gen Pharmacol 1997; 28 (4): 495–8. 65. Pollack MH. Innovative uses of benzodiazepines in psychiatry. Can J Psychiatry 1993; 38 (Suppl. 4): S122–126. 66. Pompéia S, Bueno OF, Tufik S. Lorazepam should no longer be used as a prototypical benzodiazepine. Psychopharmacology (Berl) 2003; 169 (2): 211–2. 67. Pompéia S, Manzano GM, Tufik S et al. What makes lorazepam different from other benzodiazepines? J Physiol 2005; 569 (Pt. 2): 709; author reply 710. 68. Powney MJ, Adams CE, Jones H. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2012; 11: CD009377. Полный список литературы можно посмотреть на нашем сайте в Интернете: www.con-med.ru